Digital Biomarker Development Program
Funds research to develop, validate, and translate digital biomarkers (e.g., wearables, apps, sensors) for Alzheimer's disease detection and monitoring.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates (Anticipated): February 2027 (Letter of Intent) | April 2027 (Full application)
Funding Amounts: Exploratory: up to ~$250,000; Proof-of-principle: up to ~$500,000; Validation: higher, based on scope—no strict cap; durations vary by project stage.
Summary: Supports development, validation, and translation of digital platforms (wearables, apps, sensors) for Alzheimer's disease detection and monitoring.
Key Information: Clinical collaboration required; both academic and for-profit applicants worldwide eligible; data sharing via Sage Bionetworks expected.
Description
This program funds innovative research projects focused on the development, validation, and clinical translation of digital biomarkers for Alzheimer's disease and related dementias. Supported projects may utilize wearables, mobile apps, sensors, or other digital platforms to detect or monitor disease-relevant symptom domains such as cognition, daily activities, motor function, sleep, affect, and more. The goal is to advance digital tools that have clear biological links to Alzheimer's, demonstrate clinical utility, and are scalable for broad deployment. Awardees also gain access to expert industry and regulatory consultants and are expected to share resulting data to accelerate progress in the field.
